反応式
[CH:1]([N:4]1[CH2:9][CH2:8][CH:7]([NH:10][C:11]([C:13]2[NH:17][C:16]3[CH:18]=[CH:19][CH:20]=[C:21]([O:22][CH2:23][CH2:24][O:25][CH2:26][CH3:27])[C:15]=3[N:14]=2)=[O:12])[CH2:6][CH2:5]1)([CH3:3])[CH3:2].Br[CH2:29][C:30]([NH:32][C:33]1[CH:38]=[CH:37][C:36]([Cl:39])=[CH:35][N:34]=1)=[O:31].C([O-])(=O)C>>[CH:1]([N:4]1[CH2:9][CH2:8][CH:7]([NH:10][C:11]([C:13]2[N:17]([CH2:29][C:30](=[O:31])[NH:32][C:33]3[CH:38]=[CH:37][C:36]([Cl:39])=[CH:35][N:34]=3)[C:16]3[CH:18]=[CH:19][CH:20]=[C:21]([O:22][CH2:23][CH2:24][O:25][CH2:26][CH3:27])[C:15]=3[N:14]=2)=[O:12])[CH2:6][CH2:5]1)([CH3:3])[CH3:2]参加物
4
反応物 3
生成物 1
実験手順
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2-ethoxy-ethoxy)-1H-benzoimidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide was prepared by a procedure according to example 108 (v) starting from 540.0 mg (1.44 mmol) 4-(2-Ethoxy-ethoxy)-1H-benzoimidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide and 359.8 mg (1.44 mmol) 2-bromo-N-(5-chloro-pyridin-2-yl)-acetamide. The title compound was transformed into its acetate affording a colorless amorphous material.
後処理
- custom1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-4-(2-ethoxy-ethoxy)-1H-benzoimidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide was prepared by a procedure
出典と根拠
- ORDレコード
- ord-bdf86eb853184c719967f70201c76f14
- 出典データセット
- uspto-grants-2010_06
- 特許番号
- US07741341B2
関連ノート
読み込み中…